Novo Nordisk A/S (NYSE:NVO) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Key Points

• Novo Nordisk beat quarterly estimates: EPS was $0.88 versus $0.73 expected, while revenue reached $12 billion compared with the $11.07 billion consensus.
• Obesity-treatment demand supported the outlook: Obesity sales grew 22%, and management raised its full-year guidance; Wegovy’s pill launch is seeing strong early uptake.
• Headwinds remain: Pricing pressure, patent expirations and competition weigh on the outlook, with management expecting U.S. operations to decline in 2026.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $0.88 EPS for the quarter, topping analysts' consensus estimates of $0.73 by $0.15, FiscalAI reports. The firm had revenue of $12 billion for the quarter, compared to analysts' expectations of $11.07 billion. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%.

Here are the key takeaways from Novo Nordisk A/S's conference call:

• Q3 results exceeded expectations and guidance was raised again. Adjusted sales rose 4% to DKK 79.2 billion and adjusted operating profit increased 27%, with the profit comparison benefiting from transformation costs recorded a year earlier; full-year adjusted sales and operating-profit growth are now forecast at -2% to +2%, and free cash flow at DKK 60–70 billion.
• Patient volumes and obesity demand continued to recover. Novo added 1.3 million patients in Q3, reported 22% obesity-sales growth, and said it now reaches about 48 million people with diabetes and obesity treatments.
• Wegovy’s pill launch is showing strong early traction, with about 80% of U.S. new-to-brand oral obesity prescriptions and roughly 90% market share in the U.K.; management is accelerating international rollout, while noting that uptake is normalizing after an initial launch surge.
• The pipeline and launch slate offer potential growth opportunities, including CagriSema data showing 21% weight loss in an obesity trial and the advancement of oral amycretin into Phase III. CagriSema and hemophilia treatment Frehemgo are potential upcoming launches, subject to regulatory approvals.
• Pricing pressure and patent expirations remain headwinds, and management expects U.S. operations to decline in 2026. Executives also said the U.S. obesity-drug category was relatively flat from May to October excluding the Bridge program, while international sales face additional loss-of-exclusivity and China pressures.

Novo Nordisk A/S Stock Up 5.3%

NYSE NVO traded up $2.14 during mid-day trading on Wednesday, reaching $42.33. The stock had a trading volume of 19,750,247 shares, compared to its average volume of 16,429,648. The stock has a market cap of $189.01 billion, a PE ratio of 10.35, a price-to-earnings-growth ratio of 1.37 and a beta of 0.70. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66. The company has a fifty day moving average price of $40.97 and a 200 day moving average price of $44.15.

Analysts Set New Price Targets

A number of research analysts have issued reports on NVO shares. Citigroup reiterated a "neutral" rating on shares of Novo Nordisk A/S in a research note on Friday, October 9th. DZ Bank reissued a "neutral" rating on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Cfra downgraded Novo Nordisk A/S from a "hold" rating to a "sell" rating and set a $38.00 price target for the company. in a report on Tuesday, September 22nd. UBS Group reaffirmed a "neutral" rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Five investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $59.44.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo reported quarterly EPS of $0.88, above the $0.73 consensus, and revenue of $12 billion versus estimates of $11.07 billion. Obesity-drug sales rose 22%, helping the company raise its full-year 2026 sales and operating-profit outlook. Reuters report on quarterly results and guidance
• Positive Sentiment: Wegovy pill demand was a key bright spot: the CEO said its rollout exceeded expectations. The strong uptake and an outlook upgrade that Jefferies says may leave analyst forecasts lagging could support further estimate increases. Zacks coverage of earnings and Wegovy growth
• Neutral Sentiment: Novo’s CFO Karsten Munk Knudsen is set to leave the company, creating a leadership transition to monitor. Reuters report on the CFO's departure
• Negative Sentiment: Pricing pressure and weakness in diabetes treatments temper the outlook, while impairment charges weighed on reported operating profit. Competition in obesity drugs remains another risk. Coverage of the raised outlook and quarterly performance

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.